Oregovomab

Drug Profile

Oregovomab

Alternative Names: Anti CA125 Mab oregovomab; Anti-CA125-monoclonal-antibody-B43-13-AltaRex; Anti-idiotype-ovarian-cancer-vaccine-AltaRex; Mab B43.13; Monoclonal antibody B43.13; OvaRex; Ovarian-cancer-vaccine-AltaRex

Latest Information Update: 15 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AltaRex
  • Developer National Cancer Centre (Singapore); National Cancer Institute (USA); OncoQuest; University of Nebraska Medical Center
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer; Pancreatic cancer
  • Phase I/II Peritoneal cancer

Most Recent Events

  • 02 Jun 2017 Adverse events data from a phase II trial in Ovarian cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 30 May 2017 OncoQuest initiates a phase Ib trial in Ovarian cancer (Recurrent, Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (NCT03162562)
  • 24 May 2017 OncoQuest plans a phase I trial for Ovarian cancer (Recurrent, Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (NCT03162562)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top